Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07257055 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT07257055: Recruiting Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT07257055 is a Phase 2 study that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07257055, a Phase 2 study, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
to learn if giving glofitamab after treatment with BTKi-rituximab can help to control high-risk MCL.
Interventions
- DRUG Glofitamab
- DRUG Rituximab
- DRUG Acalabrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-04-01 |
| Est. Completion | 2030-11-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07257055
The ClinicalTrials.gov registry entry for NCT07257055 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Glofitamab is the first listed.
NCT07257055 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07257055 about?
NCT07257055 is a clinical study titled "Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study". to learn if giving glofitamab after treatment with BTKi-rituximab can help to control high-risk MCL.
What is the current status of trial NCT07257055?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2026-04-01. Estimated completion is 2030-11-24.
What interventions are being tested in trial NCT07257055?
The interventions under investigation include: Glofitamab (DRUG), Rituximab (DRUG), Acalabrutinib (DRUG).
Who is sponsoring clinical trial NCT07257055?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.